Curexo Inc Cash Flow Conversion Efficiency
Curexo Inc cash flow conversion efficiency. Based on the latest financial reports, Curexo Inc (060280) has a cash flow conversion efficiency ratio of -0.016x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-1.49 Billion ≈ $-1.01 Million USD) by net assets (₩94.30 Billion ≈ $63.90 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Curexo Inc for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Curexo Inc (2012–2024)
Cash flow conversion efficiency of Curexo Inc from 2012 to 2024. This chart illustrates how Curexo Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Curexo Inc stock quote for real-time trading data and today's change.
Curexo Inc Cash Flow Conversion Ratio Explained
Curexo Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Curexo Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Curexo Inc ranked by their cash flow conversion efficiency. Review how much free cash does Curexo Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HPL Electric & Power Limited
NSE:HPL
|
0.115x |
|
DeFi Technologies Inc.
NEO:DEFI
|
-0.367x |
|
Lippo Karawaci Tbk
JK:LPKR
|
-0.016x |
|
I-MAB SPONS.ADS/1 -0001
F:0VY
|
-0.063x |
|
Batisoke Soke Cimento Sanayi TAS
IS:BSOKE
|
0.033x |
|
Waterco Ltd
AU:WAT
|
0.044x |
|
MEDICLIN Aktiengesellschaft
XETRA:MED
|
0.097x |
|
Sriracha Construction Public Company Limited
BK:SRICHA
|
0.699x |
Annual Cash Flow Conversion Efficiency for Curexo Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Curexo Inc from 2012 to 2024. Also see Curexo Inc assets under control for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩93.38 Billion ≈ $63.28 Million |
₩3.85 Billion ≈ $2.61 Million |
0.041x | -18.50% |
| 2023-12-31 | ₩100.43 Billion ≈ $68.06 Million |
₩5.08 Billion ≈ $3.44 Million |
0.051x | +131.58% |
| 2022-12-31 | ₩81.68 Billion ≈ $55.35 Million |
₩-13.08 Billion ≈ $-8.87 Million |
-0.160x | +21.40% |
| 2021-12-31 | ₩42.90 Billion ≈ $29.07 Million |
₩-8.74 Billion ≈ $-5.92 Million |
-0.204x | -496.60% |
| 2020-12-31 | ₩44.79 Billion ≈ $30.36 Million |
₩-1.53 Billion ≈ $-1.04 Million |
-0.034x | +70.40% |
| 2019-12-31 | ₩43.98 Billion ≈ $29.80 Million |
₩-5.08 Billion ≈ $-3.44 Million |
-0.115x | +46.85% |
| 2018-12-31 | ₩70.03 Billion ≈ $47.46 Million |
₩-15.20 Billion ≈ $-10.30 Million |
-0.217x | -911.18% |
| 2017-12-31 | ₩70.69 Billion ≈ $47.91 Million |
₩-1.52 Billion ≈ $-1.03 Million |
-0.021x | +97.33% |
| 2016-12-31 | ₩73.08 Billion ≈ $49.53 Million |
₩-58.79 Billion ≈ $-39.84 Million |
-0.804x | -36.21% |
| 2015-12-31 | ₩33.51 Billion ≈ $22.71 Million |
₩-19.79 Billion ≈ $-13.41 Million |
-0.591x | +58.96% |
| 2014-12-31 | ₩13.94 Billion ≈ $9.45 Million |
₩-20.06 Billion ≈ $-13.60 Million |
-1.439x | -246.31% |
| 2013-12-31 | ₩35.09 Billion ≈ $23.78 Million |
₩-14.58 Billion ≈ $-9.88 Million |
-0.416x | -4.98% |
| 2012-12-31 | ₩49.48 Billion ≈ $33.53 Million |
₩-19.59 Billion ≈ $-13.27 Million |
-0.396x | -- |
About Curexo Inc
Curexo Inc. engages in the development and sale of medical devices in Korea and internationally. Its products include ROBIN, a robot system that guides needle path induring CT-guided interventional procedure; Baidy, a medical device that assists labor by increasing intrauterine pressure which helps natural childbirth; artificial joint surgical robot; and Gait rehabilitation robot. The company als… Read more